KalVista has an estimated pro forma cash balance of $292.2 million, which is expected to fund its operations into the 2H of ...

The majority of Teva's business lies in generic and off-patent branded drugs and faces price and volume pressures that will be exacerbated as regulatory actions and other players in the drug supply ...

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) shares are trading lower Tuesday after initially jumping after the company ...

We believe there is enormous opportunity for us in the animal pharmaceuticals market, as there is a significant need to deliver medications more efficiently,” Gelteq co-founder and CEO Nathan Givoni ...

Tonix Pharmaceuticals Holding said the Food and Drug Administration has accepted its application seeking approval of its TNX-102 SL product candidate for the chronic pain condition fibromyalgia.

FDA is expected to assign a Prescription Drug User Fee Act (PDUFA) target action date and announce whether Priority Review has been granted in ...

Executives at a local company believe they have a quicker and less expensive path to get their new drug approved.

The U.S. Food and Drug Administration (FDA) signaled that it may be willing to consider granting accelerated approval to CNM-Au8 to treat amyotrophic lateral sclerosis (ALS), based on data from ...

has accepted Everest’s New Drug Application (NDA) for VELSIPITY(R) (etrasimod) for the treatment of adult patients with moderately to severely active ulcerative colitis. VELSIPITY(R) is an effective ...

Lenacapavir, a relatively new drug, provides lasting protection against HIV infection and requires a booster injection be given every six months. This marks a stark contrast to current HIV pre ...